Shares of Illumina (ILMN) Sees Large Inflow of Net Money Flow

Illumina (ILMN) : Illumina (ILMN) had a healthy money flow of $8.01 million into the stock during the Fridays trading session. The value of bullish trades on upticks was $27.19 million, whereas, investors only sold shares worth $19.18 million on downticks. The stock closed the day with an up-down ratio of 1.42.The money flow in the block trades to the tune of $6.58 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $6.58 million worth of transactions were on upticks. Illumina (ILMN) stock slid $0.55 intraday and traded at 150.76, a change of -0.36% over previous days close. However, for the week, the company shares are 1.38% compared to previous weeks close.


Illumina (ILMN) : Average target price received by Illumina (ILMN) is $156.31 with an expected standard deviation of $30.38. The most aggressive target on the stock is $235, whereas the most downbeat target is $110. 13 financial analysts are currently covering the stock.

Illumina (NASDAQ:ILMN): On Fridays trading session , Opening price of the stock was $151.96 with an intraday high of $151.96. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $149.67. However, the stock managed to close at $150.76, a loss of 0.36% for the day. On the previous day, the stock had closed at $151.31. The total traded volume of the day was 541,670 shares.

In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Illumina Inc, Epstein Robert S had sold 1,200 shares worth of $180,000 in a transaction dated July 18, 2016. In this transaction, 1,200 shares were sold at $150 per share.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.